Orthofix Medical (NASDAQ:OFIX) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Orthofix Medical (NASDAQ:OFIX) announced its quarterly earnings data on Tuesday. The medical device company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.16, FiscalAI reports. The business had revenue of $196.71 million for the quarter, compared to analysts’ expectations of $196.40 million. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%.

Here are the key takeaways from Orthofix Medical’s conference call:

• Company reported a solid start to 2026 with total net sales of $196.4M (up 3% pro forma) and reaffirmed full‑year guidance of $850–860M in net sales and $95–98M adjusted EBITDA, with positive free cash flow expected.
• Management simplified spine leadership and says distributor transitions are largely complete, positioning the business to accelerate as it pushes adoption of the 7D FLASH ecosystem and the full‑market launch of Virada in H2 2026.
• Execution with prioritized partners is driving results — the top 30 U.S. distributors grew net sales 27% YoY (24% on a trailing 12‑month basis), which management highlights as validation of its distributor strategy.
• Biologics remain a weak spot despite sequential improvement; the business was realigned under limb reconstruction leadership and management expects a return to market growth, but it represents a near‑term execution risk.
• Financial and margin trends showed improvement, with pro forma non‑GAAP adjusted gross margin at 70.7% (up 40 bps), Q1 adjusted EBITDA of $9.7M, and a cash balance of $120.9M.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX traded down $0.25 during midday trading on Wednesday, reaching $12.19. 502,781 shares of the company were exchanged, compared to its average volume of 266,247. The stock’s 50-day moving average price is $12.24 and its 200-day moving average price is $13.93. The stock has a market cap of $489.31 million, a P/E ratio of -5.21 and a beta of 0.79. Orthofix Medical has a one year low of $10.24 and a one year high of $16.99. The company has a quick ratio of 1.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.39.

Key Stories Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Q1 results beat Street expectations: Orthofix reported GAAP EPS of -$0.52 vs. consensus -$0.68 and revenue of $196.7M (in line/slightly above estimates); management reaffirmed full‑year 2026 guidance and highlighted “steady execution” after spine commercial channel changes. Read More.
• Positive Sentiment: Management commentary and the earnings call provided context on channel actions and execution; investors who focus on beat + guidance may view this as a catalyst for stabilization. Read More.
• Neutral Sentiment: Analyst/press coverage and presentation materials are available for deeper review (slides, press release and call recording), useful for modeling but not immediately directional. Read More.
• Negative Sentiment: Regulatory risk: the FDA reclassified bone growth stimulators, a move that TipRanks says raises competitive and margin pressures for Orthofix’s core products — a material negative for future pricing and margins. Read More.
• Negative Sentiment: Shareholder/legal risk: Halper Sadeh LLC is soliciting shareholders to discuss potential claims, which may signal activist or litigation risk that can pressure the stock. Read More.
• Negative Sentiment: Underlying fundamentals remain a concern: the company is still unprofitable with a negative net margin and negative ROE, and analysts model a negative full‑year EPS—factors that cap upside until margin/regulatory clarity arrives. Read More.

Insiders Place Their Bets

In other Orthofix Medical news, insider Jorge Andres Cedron sold 3,743 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $12.82, for a total transaction of $47,985.26. Following the sale, the insider owned 59,006 shares of the company’s stock, valued at approximately $756,456.92. The trade was a 5.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Engine Capital Management, Lp bought 13,061 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average cost of $12.96 per share, for a total transaction of $169,270.56. Following the purchase, the insider owned 3,673,092 shares of the company’s stock, valued at approximately $47,603,272.32. The trade was a 0.36% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.30% of the company’s stock.

Institutional Trading of Orthofix Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new stake in shares of Orthofix Medical during the fourth quarter worth $56,000. Mackenzie Financial Corp bought a new stake in shares of Orthofix Medical during the third quarter worth $148,000. Strs Ohio acquired a new position in shares of Orthofix Medical during the first quarter worth $150,000. VARCOV Co. acquired a new position in shares of Orthofix Medical during the fourth quarter worth $164,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Orthofix Medical by 21.1% during the second quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock worth $166,000 after purchasing an additional 2,589 shares during the period. Institutional investors own 89.76% of the company’s stock.

Wall Street Analyst Weigh In

OFIX has been the topic of a number of recent analyst reports. Barrington Research reissued an “outperform” rating and issued a $17.00 price objective on shares of Orthofix Medical in a research note on Friday, April 10th. Canaccord Genuity Group decreased their price objective on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Stifel Nicolaus decreased their price objective on shares of Orthofix Medical from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. TD Cowen initiated coverage on shares of Orthofix Medical in a research note on Tuesday, January 27th. They issued a “hold” rating and a $14.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.25.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.